Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...
Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback